|Day Low/High||12.50 / 12.68|
|52 Wk Low/High||6.85 / 14.37|
Rakesh Sachdev, CEO of Platform Specialty Products, tells Jim Cramer his company sees growth opportunities in Asia.
It wasn't an up day for the markets, but it's great news when a critical IPO goes off without any major problems, says Jim Cramer.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALEX, AZN, BDL, INGN, ITRI, PAH Downgrades: AGYS, ASFI, IKNX, PRFT, SIX, VNCE Initiations: SRG Read on to get TheStreet Quant Ratings' detailed report:
The chemicals name's prices are not extended and it looks like there is plenty of room on the upside.
A popular strategy is to piggy-back purchases revealed in 13F SEC filings.
The most recent short interest data was recently released for the 10/31/2016 settlement date, and Platform Specialty Products Corp is one of the most shorted stocks of the Russell 3000, based on 7.95 "days to cover" versus the median component at 6.43. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.
Platform Specialty (PAH) reported better-than-anticipated revenue for the 2016 second quarter before Monday's opening bell.
Trade-Ideas LLC identified Platform Specialty Products (PAH) as a weak on high relative volume candidate
Valeant Pharmaceuticals is not letting up on Ackman's fund, dragging 2016 losses down by more than 20%.